Navigation Links
Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
Date:11/29/2007

NEW YORK, Nov. 29 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and H. Lundbeck A/S today announced preliminary top-line results from a phase III study of LEXAPRO (escitalopram oxalate) in the treatment of adolescents, aged 12-17, with Major Depressive Disorder (MDD). These results indicate that patients treated with LEXAPRO experienced statistically significant improvement in symptoms of depression, as measured by the study's primary endpoint, the Children's Depression Rating Scale-Revised (CDRS-R), compared to placebo. The CDRS-R is a commonly used clinician-rated instrument that covers 17 symptom areas of depression relevant to adolescents, including impaired schoolwork, difficulty having fun, social withdrawal, physical complaints, and low self-esteem. Additional data from this study are expected to be presented in 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

Researchers estimate that up to eight percent of adolescents are affected by depression.(1) However, FDA-approved treatment options for this population are limited. LEXAPRO is not currently approved by the FDA for use in pediatric patients.

"Depression is a significant problem among adolescents, and frequently goes under-recognized and under-treated in this age group. These data support that LEXAPRO has potential as an effective treatment option for adolescents with depression," said Ivan Gergel, M.D., Senior Vice President of Scientific Affairs and President of the Forest Research Institute.

About the Study

A double-blind, parallel-group, placebo-controlled phase III study to evaluate the safety and
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Over 200 runners participated in ... Benefit the Radiation Oncology Institute (ROI), hosted by Radiation ... Gate Park in San Francisco.  "Donations ... CEO of Radiation Business Solutions, "but at this ... over $70,000 for the ROI this year. This surpasses ...
(Date:9/19/2014)... 2014  CytRx Corporation (Nasdaq: CYTR ), ... today announced that David J. Haen , Vice ... in the Biotech Industry Conference on Friday, September 26 th ... take place at the Millennium Broadway Hotel in ... live and archived webcast of the presentation will be ...
(Date:9/19/2014)... , September 19, 2014 Reductions ... for many years in people with diabetes type 2 ... long term benefits for the kidneys." Australian ... with type 2 diabetes leads to persistent reductions in ... The global study has found that, five ...
Breaking Medicine Technology:Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... Systems, Inc. (NASDAQ: DCTH ) announced today that ... agreement for the Delcath Hepatic CHEMOSAT ® Delivery system ... Oncologia ---IEO), a premier European cancer treatment and research center ... the Company will provide the IEO with logistics and clinical ...
... Reportlinker.com announces that a new ... its catalogue: , Frost & ... http://www.reportlinker.com/p0490686/Frost--Sullivan-Speaks-Candidly-with-US-Pharmacists.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmacies_and_Drug_Stores ... feedback provided by a healthcare pharmacist ...
Cached Medicine Technology:Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union 2Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union 3Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union 4Frost & Sullivan Speaks Candidly with U.S. Pharmacists 2Frost & Sullivan Speaks Candidly with U.S. Pharmacists 3
(Date:9/19/2014)... Dallas, TX (PRWEB) September 19, 2014 ... which introduces a traditional Scandinavian style of ... United States. Much like Diet Doc’s medical ... Diet emphasizes cooking and eating good food ... diet also focuses on teaching patients to ...
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... by technological advancements, surgical techniques, and immunosuppressant drugs ... preferred treatment for several chronic diseases related to ... in organ and tissue transplantation have phenomenally revolutionized ... Organ transplant today represents a pivotal medical ...
(Date:9/19/2014)... as Johne,s disease, is caused by the bacterium ... Austria, there is a legal obligation to report ... treatment-resistant diarrhoea and wasting among affected animals. The ... farms. The animals produce less milk, exhibit fertility ... such as udder inflammation. , To date ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 InventHelp, ... clients, an inventor from New York, has created an accessory ... from inclement weather or smoke during transport. This invention ... to a stretcher and remain in place until removed, guarding ... a more comfortable move with protection from irritating smoke or ...
(Date:9/19/2014)... as released a new blog post announcing ... for life insurance. , Clients who have heart disorders ... not require medical examinations. No medical exam life insurance ... minutes. , Some traditional policies (that require medical ... health problems, however the application time is longer and ...
Breaking Medicine News(10 mins):Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Lymphatic fluid used for first time to detect bovine paratuberculosis 2Health News:InventHelp® Client Patents “Patient Protector” – Designed to Protect Patients During Transport 2Health News:No Medical Exam Life Insurance For Clients Who Have Heart Problems! 2
... should reduce the salt intake to avoid high blood pressure and ... g per day//. FSA also stressed that the tinned foods should ... ,Too much of salt is very harmful to humans ... can lead to heart attacks. The amount of salt content is ...
... following ace cricketer Sachin Tendulkar's and several other players complaining ... the sports arena//. ,Tennis elbow, or lateral epicondylitis ... where the outer part of the elbow becomes painful and ... or a direct bang. The problem occurs following overuse of ...
... at high risk of fatal and non-fatal myocardial ... reason for their decreased life expectancy//. There is ... (PPAR-?) could reduce macrovascular complications. Pioglitazone is one ... ,A recent study, published in the October issue ...
... for cardiovascular disease in both men and women, which ... subjects and that 80 percent of all type 2 ... In these patients hyperglycemia per se confers ... of even borderline-high-risk LDL-C signals the need for more ...
... Odors have long been known to be capable of ... effects of essential oils have been acknowledged in folk ... lavender fragrances have been particularly attributed with mood enhancing ... the September issue of the journal Physiology & Behavior, ...
... the benefits of oral ZYVOX for the treatment of ... compared data from 80 health care clinics and compared ... The results show that oral tablets of Linezolid (ZYVOX), ... to health clinics compared to vancomycin. ,This ...
Cached Medicine News:Health News:Tennis elbow not new among cricketers, say experts 2Health News:Aromatherapy: Ambient odors of orange and lavender reduce anxiety 2Health News:Oral use of ZYVOX (Linezolid) is better to Intravenous Vancomycin use for Skin Infections 2
Precision that fits in the palm of your hand and measures down to 125 microns, the Pocket Pachymeter is about 8" X 4" x 2" and really does fit in a lab coat pocket or briefcase....
15 segment Vertical Prism Bar provides 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30 PD (Note: 30 PD is on the bar). 4447 xx Vertical Prism Bar....
Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Sabre 180, 230V, 50Hz is a powerful niche generator....
Medicine Products: